DKFZ: A healthy lifestyle reduces the risk of colon cancer – regardless of the genetic risk profile

On September 18, 2018, Posted by , In News, By , , With Comments Off on DKFZ: A healthy lifestyle reduces the risk of colon cancer – regardless of the genetic risk profile

The risk of developing bowel cancer depends, among other things, on lifestyle. Scientists from the German Cancer Research Center were able to show that everyone can reduce their personal risk of colon cancer by combining as many of five healthy lifestyles as possible: non-smoking, low alcohol consumption, a healthy diet,…

DKFZ: Figures for Germany determined for the first time: Avoidable risk factors cause 37 percent of all cancer cases

On September 10, 2018, Posted by , In News, By , , With Comments Off on DKFZ: Figures for Germany determined for the first time: Avoidable risk factors cause 37 percent of all cancer cases

How many cancer cases in Germany are attributable to risk factors that we can influence ourselves? How many cancer cases are linked to cigarette smoking, being overweight or physical inactivity and, thus, are potentially preventable? Scientists from the German Cancer Research Center (DKFZ) have now calculated these figures for Germany…

HS-Analysis: how softwares can contribute to cancer treatment development

On August 23, 2018, Posted by , In News, By , , With Comments Off on HS-Analysis: how softwares can contribute to cancer treatment development

Finding a cure to any type of cancer is one of the biggest challenge in medicine. HS-Analysis wants to bring the concer research forward with the help of a software. Read about the plans of Sergey Biniaminov (Managing Director of HS Analysis) in the interview with ka-news (in German).

EMBL: New approach for testing cancer drug response

On August 23, 2018, Posted by , In News, By , , With Comments Off on EMBL: New approach for testing cancer drug response

  New approach uses inherited genome to test cancer drug response. PHOTO: iStock Large-scale systematic analysis explores how inherited genome effects drug response of cancer cells Patients with seemingly similar cancer tumours can respond differently to the same treatment. Over the last decades, scientists have been studying the molecular signatures…

DKFZ: Combined imaging provides more information about the tumor

On August 13, 2018, Posted by , In News, By , , With Comments Off on DKFZ: Combined imaging provides more information about the tumor

The German Cancer Research Center (DKFZ) has installed the world’s first combined device combining a 9.4 Tesla high-field MRI with a PET scanner. In combination, the two imaging methods provide significantly more information about tumors. © S. Kegel/DKFZ A variety of imaging procedures provide insights into the body’s interior. Each…

DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

On July 11, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: Brain cancer – Typical mutation in cancer cells stifles immune response

The exchange of a single amino acid building block in a metabolic enzyme can lead to cancer. In addition, it can impair the immune system, scientists from the German Cancer Research Center (DKFZ), the University Hospitals in Mannheim and Heidelberg, and the German Cancer Consortium now report. It thus blocks…

BioRN Lounge: Dr. Juergen Gamer talked about Apogenix attractive immuno-oncology pipeline.

On June 27, 2018, Posted by , In Press Releases, By , , With Comments Off on BioRN Lounge: Dr. Juergen Gamer talked about Apogenix attractive immuno-oncology pipeline.

Heidelberg, 27.06.2018 BioRN Lounge: Dr. Juergen Gamer talked about “TNF Superfamily Receptor Modulators – Innovative Immuno-oncology Therapeutics” Once again, the BioRN Lounge was the occasion for the life science companies as well for scientists from our research institutes, to meet and chat about latest news and achievements. The BioRN Lounge…

DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

On June 27, 2018, Posted by , In News, By , , With Comments Off on DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

Chronic lymphocytic leukemia (CLL) is the most common type of blood cancer in adults. It can be treated with chemotherapy and oral drugs but this treatment cannot cure the cancer completely. Although the human immune system is capable of fighting the cancer cells, it often fails to notice them early…

DKFZ: 14 new breast cancer risk genes discovered

On June 26, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: 14 new breast cancer risk genes discovered

Many genetic markers associated with the familial breast cancer risk are outside the protein-coding regions of the genome and are likely to regulate the activity of neighboring genes. In a large international network, in which numerous DKFZ researchers were also involved, scientists have now combined genome-wide association studies with an…

EMBL: Miniature testing of drug pairs on tumour biopsies

On June 25, 2018, Posted by , In News, By ,, , With Comments Off on EMBL: Miniature testing of drug pairs on tumour biopsies

Microfluidic device in the Merten lab. IMAGE – Ramesh Utharala, EMBL Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised…